BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/30/2026 1:40:20 PM | Browse: 2 | Download: 0
 |
Received |
|
2025-11-14 04:02 |
|
Peer-Review Started |
|
2025-11-14 04:03 |
|
First Decision by Editorial Office Director |
|
2025-12-25 08:45 |
|
Return for Revision |
|
2025-12-25 08:45 |
|
Revised |
|
2026-01-07 14:11 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-26 02:51 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-26 09:07 |
|
Articles in Press |
|
2026-01-26 09:07 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-26 05:48 |
|
Publish the Manuscript Online |
|
2026-06-30 13:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hou-Shu Tu, Meng-Lin Chen, Jing Hong and Ling He |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ling He, Chief Physician, PhD, Professor, Department of Gastroenterology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, No. 445 Bayi Avenue, Nanchang 330006, Jiangxi Province, China. heling118@126.com |
| Key Words |
Helicobacter pylori; Vonoprazan-amoxicillin dual therapy; First-line eradication; Antibiotic resistance; Pharmacogenetics; Gut microbiome; Treatment optimization; Antimicrobial stewardship |
| Core Tip |
Vonoprazan-amoxicillin dual therapy is a potent, well-tolerated first-line regimen for Helicobacter pylori eradication, even in regions with clarithromycin resistance. This opinion review integrates multicenter evidence, pharmacogenetics, and microbiome considerations, highlights unresolved controversies, and proposes a sequential roadmap for safe, globally applicable implementation and reduce the global burden of associated gastrointestinal disease. |
| Publish Date |
2026-06-30 13:40 |
| Citation |
Tu HS, Chen ML, Hong J, He L. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives. World J Gastroenterol 2026; 32(26): 116530
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i26/116530.htm |
| DOI |
https://doi.org/10.3748/wjg.116530 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
